RICHMOND, Va. & SEATTLE, Wash. & COLWORTH, England--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (APHB.PK), the leader in the development of bacteriophage-based anti-bacterial therapies to treat drug resistant infections, today provides the following update to shareholders on progress made during 2011.
